May Complement News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Shutterstock (2)
A medication approved to treat type 2 diabetes may help people with obesity lose 10 to 15 percent of their body weight an amount that healthcare professionals say could help reduce the risk for serious chronic illnesses.
Semaglutide, sold under the brand names Ozempic and Rybelsus, helped most people with obesity in a clinical trial lose at least 10 percent of their body weight, and more than half of them reduced their weight by at least 15 percent, according to the study results, which were published in February 2021 in the
The study focused on a once-weekly injection of semaglutide at a higher dose than is approved for treatment of type 2 diabetes. The drug’s manufacturer, Novo Nordisk, is now seeking approval from the U.S. Food and Drug Administration (FDA) to sell a weekly injected version of the medication as a weight loss aid. ....

United States , Baton Rouge , Frank Greenway , Beverly Tchang , Robert Kushner , Pennington Biomedical Research Center , Drug Administration , Northwestern University Feinberg School Of Medicine , Novo Nordisk , New England Journal , Northwestern University Feinberg School , Connection Between , May Complement , Healthy Lifestyle , Increase Weight , Doctor About , Weill Cornell Medicine , Pulled From Market Due , Potential Cancer , Current Obesity , Weight Loss That Actually , ஒன்றுபட்டது மாநிலங்களில் , தடியடி ரூஜ் , வெளிப்படையான கிரீன்வே , ராபர்ட் குஷ்னர் , பென்னிங்டன் உயிர் மருத்துவ ஆராய்ச்சி மையம் ,